Treatment of Sexually Transmitted Bacterial Diseases in Pregnant Women

Abstract

Testing for and treating sexually transmitted diseases (STDs) in pregnant women deserves special attention. Treatment possibilities are limited because of potential risks for the developing fetus, and because effects can differ in pregnant compared with non-pregnant women, re-infection may be missed because of the intrinsic delicacy of contact-tracing during pregnancy and because pregnant women are more reluctant to take the prescribed medication in its full dose, if at all. However, the devastating effects of some of these genital infections far outweigh any potential adverse effects of treatment. Although active syphilis has become a rarity in most Western countries, it is still prevalent in South America, Africa and South-East Asia. Benzathine benzylpenicillin (2.4 million units once or, safer, twice 7 days apart) is the treatment of choice, although patients with syphilis of longer standing require 3 weekly injections as well as extensive investigation into whether there has been any damage due to tertiary syphilis. Despite declining rates of gonorrhea, the relative rate of penicillinase-producing strains is increasing, especially in South-East Asia. The recommended treatment is intramuscular ceftriaxone (125 or 250 mg) or oral cefixime 400 mg. Despite good safety records after accidental use, fluoroquinolones are contraindicated during pregnancy. An alternative to a fluoroquinolone in pregnant women with combined gonorrhea and chlamydial infection is oral azithromycin 1 or 2 g. Azithromycin as a single 1 g dose is also preferable to a 7 day course of erythromycin 500 mg 4 times a day for patients with chlamydial infection. Eradication of Haemophilus ducreyi in patients with chancroid can also be achieved with these regimens or intramuscular ceftriaxone 250 mg. Trichomonas vaginalis, which is often seen as a co-infection, has been linked to an increased risk of preterm birth. Patients infected with this parasite should therefore received metronidazole 500 mg twice daily for 7 days as earlier fears of teratogenesis in humans have not been confirmed by recent data. Bacterial vaginosis is also associated with preterm delivery in certain risk groups, such as women with a history of preterm birth or of low maternal weight. Such an association is yet to be convincingly proven in other women. The current advice is to treat only women diagnosed with bacterial vaginosis who also present other risk factors for preterm delivery. The treatment of choice is oral metronidazole 1 g/day for 5 days. The possible reduction of preterm birth by vaginally applied metronidazole or clindamycin is still under investigation. In general, both test of cure and re-testing after several weeks are advisable in most pregnant patients with STDs, because partner notification and treatment are likely to be less efficient than outside pregnancy and the impact of inadequately treated or recurrent disease is greater because of the added risk to the fetus. Every diagnosis of an STD warrants a full screen for concomitant genital disease. Most ulce...

Anaerobes and Bacterial Vaginosis in Pregnancy: Virulence Factors Contributing to Vaginal Colonisation

“…BVAB have been reported in HIV-positive women with BV [65] and are considered to be acquired from external reservoirs such as the anus [66]. Also associated with BV infection in HIV-positive women are M. hominis and a combination of Bacteroides , Prevotella , Leptotrichia , Atopobium and Gardnerella [49,67,68,69,70,71,72] known to attract CD4 cells to the mucosa, with a concomitant reduction in lactobacilli [67]. Among the Gram-positive anaerobic cocci known to colonise the vagina are Peptococcus , Peptostreptococcus , Peptoniphilus and Anaerococcus .…”

Intermittent preventive treatment for malaria in pregnancy in Africa: What's new, what's needed?

“…Azithromycin has been used extensively to treat sexually-transmitted and other bacterial infections during pregnancy in total treatment doses of up to 1–2 g and is considered a safe alternative for the treatment of chlamydia, mycoplasma and group B streptococci in pregnant women who are allergic to beta-lactam antibiotics [71-73]. …”

“…Sexually-transmitted infections (STIs) are common in women of childbearing age in Africa and may go undiagnosed and untreated during pregnancy[127]. Monthly azithromycin reduces STI incidence significantly in high-risk groups[128] and is safe and effective for treating gonorrhoea as well as chlamydia infection during pregnancy[71], which is associated with increased risk of stillbirth, prematurity and LBW[129]. Mefloquine-azithromycin may, therefore, represent a promising, safe and effective combination for IPTp and should be considered urgently for evaluation in phase III clinical trials.…”

Recent Sex Trade and Injection Drug Use Among Opiate and Cocaine-dependent Pregnant Women in Treatment

“…Unfortunately, there is a paucity of approaches to the treatment of opioid and cocaine dependence developed to address the unique challenges presented by drug dependent pregnant women 4–7. A particular concern with substantial significance to the health of both the pregnant mother and the fetus concerns the degree to which pregnant women with drug dependence exhibit sexual or injection risk behavior that may predispose them to contract HIV8 or other infectious diseases including sexually transmitted infections, such as syphilis, gonorrhea, and trichomonas 9, 10…”

“…Thus, extant study findings among drug dependent women in treatment suggests that a co-existing psychiatric symptoms may place women at heightened risk to contract HIV and other infectious diseases by virtue of elevated risk behavior associated with psychiatric disorder status. This relationship between psychiatric disorder status and elevated infectious disease risk is particularly relevant to opioid and cocaine dependent women who are pregnant because both the diseases themselves and the treatments for the diseases may adversely affect the health of both mothers and their fetuses 9, 10, 21, 22…”